ACAD vs UBER · P/E 15, rev $957.8M vs P/E 18, rev $52.02B
ACADIA Pharmaceuticals Inc (ACAD) versus Uber Technologies Inc (UBER) — a side-by-side from cached financials, not a winner call.
ACADIA Pharmaceuticals Inc (ACAD) is a biotechnology company listed on US.
Uber Technologies Inc (UBER) is a software - application company listed on NYSE. It is led by Dara Khosrowshahi.
Latest reported ACAD revenue for 2024-12-31 was $957.8M. Net income was $226.5M. Revenue was up 314.6% from 2023-12-31 to 2024-12-31. ACAD currently screens at market cap $3.51B and trailing P/E 15.3.
Latest reported UBER revenue for 2025-12-31 was $52.02B. Net income was $10.05B. Revenue was up 18.3% from 2024-12-31 to 2025-12-31. UBER currently screens at market cap $144.34B and trailing P/E 17.6.
ACAD currently screens at market cap $3.51B and trailing P/E 15.3. UBER currently screens at market cap $144.34B and trailing P/E 17.6.
Not investment advice. Open the ACAD and UBER stock pages for the full models.
Not investment advice.